摘要
目的评价门冬胰岛素治疗妊娠期糖尿病(GDM)的可行性及安全性。方法选取2011年10月-2014年10月本院收治的80例GDM患者,随机分为观察组和对照组,每组40例。观察组采用门冬胰岛素治疗,对照组采用生物合成人胰岛素治疗。观察并比较两组治疗前后空腹血糖(FPG)、餐后2 h血糖(2 h PG)及血浆糖化血红蛋白(Hb A1c)水平,同时记录两组并发症的发生情况。结果治疗前,两组的FPG、2 h PG及Hb A1c水平比较,差异无统计学意义(P〉0.05);治疗后,两组较治疗前的各指标均有改善,与治疗前差异有统计学意义(P〈0.05),且治疗后观察组与对照组比较,差异有统计学意义(P〈0.05);观察组的并发症总发生率为12.5%,对照组为32.5%,两组差异有统计学意义(χ^2=5.8039,P=0.0160)。结论采用门冬胰岛素治疗GDM可显著改善患者的临床症状,降低并发症发生率,安全有效,值得临床推广。
Objective To evaluate the feasibility and safety of insulin aspart in the treatment of gestational diabetes mellitus(GDM). Methods 80 patients with GDM admitted into our hospital from October 2011 to October 2014 were selected and evenly divided into observation group and control group in random.Observation group was used insulin aspart,while control group was adopted biosynthetic human insulin.Fasting plasma glucose(FPG),2 hours plasma glucose(2 h PG),and the level of glycosylated hemoglobin(Hb A1c) between two groups was observed and compared.At the same time,the occurrence of complications between two groups was recorded. Results Before treatment,FPG,2 h PG and Hb Alc in two groups was compared,the difference was no significant(P〉0.05).After treatment,indexes in two groups was improved compared with prior treatment,the difference was significant(P〈0.05).Differences in observation group had statistical significances after treatment in comparison with those in control group(P〈0.05).The total incidence of complications in observation group was 12.5%,while the control group was 32.5%,the difference was significant(χ^2=5.8039,P=0.0160). Conclusion Application of insulin aspart to treat GDM can significantly improve patient′s clinical symptoms,reduce the incidence of complications,which is safe and effective,it is worthy of clinical promotion.
出处
《中国当代医药》
2015年第17期126-128,共3页
China Modern Medicine
关键词
门冬胰岛素
妊娠期糖尿病
可行性
安全性
Insulin aspart
Gestational diabetes mellitus
Feasibility
Safety